STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Short Interest Up 84.2% in August

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 3,500 shares, an increase of 84.2% from the August 15th total of 1,900 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily trading volume, of 25,400 shares, the short-interest ratio is currently 0.1 days.

STRATA Skin Sciences Stock Down 7.7 %

Shares of NASDAQ SSKN traded down $0.25 during midday trading on Friday, reaching $3.01. 8,397 shares of the company’s stock traded hands, compared to its average volume of 11,780. The company has a market cap of $12.55 million, a price-to-earnings ratio of -0.91 and a beta of 1.37. STRATA Skin Sciences has a one year low of $2.51 and a one year high of $10.00. The company has a quick ratio of 0.92, a current ratio of 1.14 and a debt-to-equity ratio of 1.59. The stock’s 50 day simple moving average is $3.16 and its 200-day simple moving average is $3.83.

STRATA Skin Sciences (NASDAQ:SSKN) last announced its quarterly earnings results on Wednesday, August 14th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter. The company had revenue of $8.44 million during the quarter. STRATA Skin Sciences had a negative net margin of 25.40% and a negative return on equity of 50.45%. On average, analysts predict that STRATA Skin Sciences will post -1 EPS for the current fiscal year.

Insider Buying and Selling at STRATA Skin Sciences

In related news, Director Uri Geiger bought 230,573 shares of STRATA Skin Sciences stock in a transaction dated Monday, July 15th. The shares were acquired at an average cost of $3.14 per share, with a total value of $723,999.22. Following the completion of the transaction, the director now owns 1,441,835 shares in the company, valued at approximately $4,527,361.90. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Uri Geiger bought 230,573 shares of the stock in a transaction on Monday, July 15th. The stock was acquired at an average cost of $3.14 per share, for a total transaction of $723,999.22. Following the acquisition, the director now owns 1,441,835 shares of the company’s stock, valued at $4,527,361.90. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Dolev Rafaeli purchased 19,100 shares of the business’s stock in a transaction dated Monday, July 15th. The shares were purchased at an average price of $3.14 per share, for a total transaction of $59,974.00. Following the purchase, the chief executive officer now owns 143,156 shares of the company’s stock, valued at approximately $449,509.84. The disclosure for this purchase can be found here. 40.43% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On STRATA Skin Sciences

A hedge fund recently raised its stake in STRATA Skin Sciences stock. Azzad Asset Management Inc. ADV lifted its position in STRATA Skin Sciences, Inc. (NASDAQ:SSKN) by 289.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 67,000 shares of the medical device company’s stock after buying an additional 49,800 shares during the period. Azzad Asset Management Inc. ADV owned approximately 0.19% of STRATA Skin Sciences worth $25,000 as of its most recent SEC filing. Institutional investors own 32.43% of the company’s stock.

STRATA Skin Sciences Company Profile

STRATA Skin Sciences, Inc, a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment.